Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Darwin AG is a prominent player in the pharmaceutical and biotechnology sector, specializing in the development, manufacturing, and distribution of therapeutic medications and healthcare solutions. The company emphasizes innovation in drug development, focusing on creating effective treatments for various complex and rare diseases. With a robust pipeline of research initiatives, Darwin AG is dedicated to addressing unmet medical needs, leveraging advanced technology and scientific expertise. Operating globally, Darwin AG serves healthcare providers, clinics, and pharmaceutical companies, impacting sectors such as oncology, neurology, and immunology. The company's contributions to the pharmaceutical market underscore its commitment to improving patient outcomes and advancing healthcare solutions. Through strategic partnerships and collaborations with research institutions and healthcare organizations, Darwin AG plays a vital role in facilitating medical advancements and improving accessibility to necessary treatments. Its position in the market is critical, as it contributes to the development of breakthrough therapies and supports healthcare systems in improving global health standards.
The business is unprofitable at the operating level (-19.85% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 114.7%, still solid. Margins contracted 124.1pp, which offsets some of the top-line progress.
ROIC dropped from 17.52% to -5.00%, capital efficiency is deteriorating. Negative free cash flow of -€22M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€54M
▲ +114.7% YoY
Net Income (TTM)
€545K
▼ -97.0% YoY
Op. Margin
-19.85%
▼ -124.1pp YoY
ROIC
-5.00%
▼ -22.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€22M
▲ +26.0% YoY
Op. Cash Flow (TTM)
€18M
▲ +13.8% YoY
Net Debt
-€47M
Net Cash Position
Cash & Equiv.
€53M
3Y CAGR: -36.3%
Continue Research